Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid

Archives of Dermatology

Volumn 136, Issue 2, 2000, Pages 174-178

  Schmidt, Enno ^a   Obe, Karin ^a   Bröcker, Eva Bettina ^a   Zillikens, Detlef ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CORRELATION FUNCTION; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PEMPHIGOID; PRIORITY JOURNAL;

EID: 0033964612     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.136.2.174     Document Type: Article

References (33)

1. Zillikens Z, Giudice GJ, Diaz LA. Bullous pemphigoid: an autoimmune blistering disease of the elderly. J Geriatr Dermatol. 1996;4:35-41.
2. Labib RS, Anhalt GJ, Patel HP, Mutasim DF, Diaz LA. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol. 1986;136:1231-1235.
3. Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol. 1992;99:243-250.
4. Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell. 1981;24:897-903.
5. Stanley JR, Tanaka T, Mueller S, et al. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest. 1988; 82:1864-1870.
6. Tanaka T, Korman NJ, Shimizu H, et al. Production of rabbit antibodies against carboxy-terminal epitopes encoded by bullous pemphigoid cDNA. J Invest Dermatol. 1990;94:617-623.
7. Bedane C, McMillan JR, Balding SD, et al. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J Invest Dermatol. 1997;108:901-907.
8. Masunaga T, Shimizu H, Yee C, et al. The extracellular domain of BPAG2 localizes to anchoring filaments and its carboxyl terminus extends to the lamina densa of normal human epidermal basement membrane. J Invest Dermatol. 1997;109:200-206.
9. Zillikens D, Giudice GJ. BP180/type XVII collagen: its role in acquired and inherited disorders of the dermal-epidermal junction. Arch Dermatol Res. 1999;291: 187-194.
10. Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Liu Z, Diaz LA. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol. 1993;151:5742-5750.
11. Zillikens D, Rose PA, Balding SD, et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol. 1997;109:573-579.
12. Zillikens D, Mascara JM, Rose PA, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol. 1997;109:679-683.
13. Liu Z, Diaz LA, Troy JL, et al. A passive transfer mouse model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest. 1993;92:2480-2488.
14. Liu Z, Diaz LA, Swartz SJ, Troy JL, Fairley JA, Giudice GJ. Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. J Immunol. 1995;155:5449-5454.
15. Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol. 1992;26:585-589.
16. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid: clinical and immunologic follow-up after successful therapy. Arch Dermatol. 1977;113:1043-1046.
17. Zillikens D, Ambach A, Schuessler M, Dummer R, Hartmann AA, Burg G. The interleukin-2 receptor in lesions and serum of bullous pemphigoid. Arch Dermatol Res. 1992;284:141-145.
18. Hornschuh B, Hamm H, Wever S, et al. Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol J Am Acad Dermatol. 1997;36:101-103.
19. Zillikens D, Kawahara Y, Ishiko A, et al. A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol. 1996;106:1333-1338.
20. Jones RH, Boadi-Boateng F. Unequally spaced longitudinal data with AR(1) serial correlation. Biometrics. 1991;47:161-175.
21. Lever WF. Pemphigus and pemphigoid: a review of the advances made since 1964. J Am Acad Dermatol. 1979;1:2-31.
22. Matsumura K, Amagai M, Nishikawa T, Hashimoto T. The majority of bullous pemphigoid and herpes gestationis serum samples read with the NC16A domain of the 180 kDa bullous pemphigoid antigen. Arch Dermatol Res. 1996;288:507-509.
23. Nakatani C, Muramatsu T, Shirai T. Immunoreactivity of bullous pemphigoid autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins. Br J Dermatol. 1998;139:365-370.
24. Pas HH, de Jong MCJM, Jonkman MF, Heeres K, Slijper-Pal IJ, van der Meer JB. Bullous pemphigoid: serum antibody titre and antigen specificity. Exp Dermatol. 1995;4:372-376.
25. Ghohestani RF, Cozzani E, Kanitakis J, Nicolas JF, Faure M, Claudy AL. BPAg2 antibodies are present at lower levels than BPAg1 antibodies in serum from patients with bullous pemphigoid. Eur J Dermatol. 1996;6:491-494.
26. Schaller J, Giese T, Ladusch M, Haustein UF. Interleukin-2 receptor expression and interleukin-2 production in bullous pemphigoid. Arch Dermatol Res. 1990; 282:223-226.
27. Delaporte E, Dubost-Brama A, Ghohestani R, et al. IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid. J Immunol. 1996;157:3642-3647.
28. D'Auria L, Fei PC, Pietravalle M, et al. The serum levels of sE-selectin are increased in patients with bullous pemphigoid or pemphigus vulgaris: correlation with the number of skin lesions and recovery after corticosteroid therapy. Br J Dermatol. 1997;137:59-64.
29. Ameglio F, D'Auria L, Bonifati C, Ferraro C, Masrtroiani A, Giacalone B. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity. Br J Dermatol. 1998;138:611-614.
30. Gammon WR, Merrit CC, Lewis DM, et al. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibod-ies, leukocytes, and complement. J Invest Dermatol. 1982;78:285-290.
31. Naito K, Morioka S, Ogawa H. The pathogenic mechanisms of blister formation in bullous pemphigoid. J Invest Dermatol. 1982;79:303-306.
32. Humbert P, Treffel P, Chapuis J-F, et al. The tetracyclines in dermatology. J Am Acad Dermatol. 1991;25:691-697.
33. Burger DR, Vandenbark AA, Daves D, Anderson WA, Vetto RM, Finke P. Nicotinamide: suppression of lymphocytic transformation with a component identified in human transfer factor. J Immunol. 1976;117:797-801.